ClinicalTrials.gov
ClinicalTrials.gov Menu

CTCs for High Grade Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02558335
Recruitment Status : Unknown
Verified April 2016 by Abramson Cancer Center of the University of Pennsylvania.
Recruitment status was:  Recruiting
First Posted : September 24, 2015
Last Update Posted : April 13, 2016
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

Brief Summary:
The purpose of this study is to identify and quantify circulating tumor markers, which are associated with the presence of tumors. The current imaging available does not allow specificity of tumor size as it relates to pseudoprogression (a temporary enlargement or "swelling" of the tumor after treatment before it shrinks). Our hope is that CTCs will provide a more accurate description of tumor state for high grade glioma patients.

Condition or disease
Stage III and IV Glioma Patients

Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Circulating Tumor Markers for High Grade Glioma
Study Start Date : April 2013
Estimated Primary Completion Date : April 2017

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. to identify and quantify circulating tumor markers [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
22 cc of blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
1. Patients with grade III and IV glioma
Criteria

Inclusion Criteria:

  • Patients with biopsy-proven high grade glioma who are undergoing definitive radiotherapy as a part of their treatment regimen or patients with radiographic appearance of high grade glioma
  • Age 18 or older
  • Signed informed consent

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02558335


Contacts
Contact: Robert Lustig, MD 855-216-0098 PennCancerTrials@emergingmed.com

Locations
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Robert Lustig, MD    855-216-0098    PennCancerTrials@emergingmed.com   
Principal Investigator: Robert Lustig, MD         
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
Investigators
Principal Investigator: Robert Lustig, MD Abramsvaniaon Cancer Center of the University of Pennsyl

Responsible Party: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier: NCT02558335     History of Changes
Other Study ID Numbers: UPCC 09313
First Posted: September 24, 2015    Key Record Dates
Last Update Posted: April 13, 2016
Last Verified: April 2016

Additional relevant MeSH terms:
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue